AAPL328.21+3.25 (+1.00%) ▲|ABBV260.21-1.51 (-0.58%) ▼|ABT108.79-1.68 (-1.52%) ▼|ACN193.12+5.44 (+2.90%) ▲|ADBE285.75+5.96 (+2.13%) ▲|AMAT435.91-2.55 (-0.58%) ▼|AMD456.16-0.90 (-0.20%) ▼|AMGN444.12+1.28 (+0.29%) ▲|AMT177.75+4.83 (+2.79%) ▲|AMZN258.90+3.92 (+1.54%) ▲|AVGO357.16-10.08 (-2.74%) ▼|AXP329.82-0.16 (-0.05%) ▼|BA210.51+1.64 (+0.79%) ▲|BAC63.04+0.44 (+0.70%) ▲|BKNG195.13-4.47 (-2.24%) ▼|BLK1,126.15+19.07 (+1.72%) ▲|BMY68.09+0.43 (+0.64%) ▲|BNY164.33+2.29 (+1.41%) ▲|BRK-B508.13+2.89 (+0.57%) ▲|C138.14+3.80 (+2.83%) ▲|CAT800.14+7.86 (+0.99%) ▲|CL90.09-0.01 (-0.01%) ▼|CMCSA26.65-0.16 (-0.60%) ▼|COF220.50+3.90 (+1.80%) ▲|COP135.72-1.48 (-1.08%) ▼|COST925.41-3.07 (-0.33%) ▼|CRM264.43+7.50 (+2.92%) ▲|CSCO108.61-0.85 (-0.77%) ▼|CVS97.20-0.03 (-0.03%) ▼|CVX211.32-0.46 (-0.22%) ▼|DE694.41-3.96 (-0.57%) ▼|DHR211.03+1.12 (+0.53%) ▲|DIS107.16-0.82 (-0.76%) ▼|DUK121.40+0.84 (+0.70%) ▲|EMR150.21+1.23 (+0.83%) ▲|FDX324.31+7.77 (+2.45%) ▲|GD365.87+1.80 (+0.49%) ▲|GE333.48+3.98 (+1.21%) ▲|GEV941.84+19.90 (+2.16%) ▲|GILD151.22+1.61 (+1.08%) ▲|GM87.22+2.35 (+2.77%) ▲|GOOG339.08+5.30 (+1.59%) ▲|GOOGL342.48+5.36 (+1.59%) ▲|GS1,037.93+33.51 (+3.34%) ▲|HD318.07+1.89 (+0.60%) ▲|HON207.63+1.56 (+0.76%) ▲|IBM234.71+3.01 (+1.30%) ▲|INTC91.67+1.62 (+1.80%) ▲|INTU344.30+1.36 (+0.40%) ▲|ISRG369.83-2.05 (-0.55%) ▼|JNJ278.43+3.22 (+1.17%) ▲|JPM362.06+5.84 (+1.64%) ▲|KO88.81+0.57 (+0.65%) ▲|LIN482.19-3.66 (-0.75%) ▼|LLY1,159.60-0.48 (-0.04%) ▼|LMT532.95+1.40 (+0.26%) ▲|LOW201.90+2.06 (+1.03%) ▲|LRCX292.66+4.34 (+1.51%) ▲|MA585.71-2.43 (-0.41%) ▼|MCD259.63-1.32 (-0.51%) ▼|MDLZ61.45-1.00 (-1.60%) ▼|MDT93.10+0.92 (+1.00%) ▲|META610.68+17.83 (+3.01%) ▲|MMM168.31-0.44 (-0.26%) ▼|MO69.49-0.07 (-0.10%) ▼|MRK152.34+0.70 (+0.46%) ▲|MS217.15+5.33 (+2.52%) ▲|MSFT510.12+13.30 (+2.68%) ▲|MU958.16+2.08 (+0.22%) ▲|NEE84.06+0.96 (+1.16%) ▲|NFLX82.67-0.06 (-0.07%) ▼|NKE38.77+0.53 (+1.39%) ▲|NOW145.59+8.87 (+6.49%) ▲|NVDA228.45+4.04 (+1.80%) ▲|ORCL154.04+8.29 (+5.69%) ▲|PEP140.02-0.50 (-0.36%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG146.92-0.72 (-0.49%) ▼|PLTR182.53+13.07 (+7.71%) ▲|PM186.17-1.77 (-0.94%) ▼|QCOM168.57-0.47 (-0.28%) ▼|RTX202.13+1.35 (+0.67%) ▲|SBUX105.82-0.90 (-0.84%) ▼|SCHW110.38+2.14 (+1.98%) ▲|SO88.77+0.46 (+0.52%) ▲|SPG211.52+1.32 (+0.63%) ▲|T26.19+0.24 (+0.92%) ▲|TMO618.43+9.89 (+1.63%) ▲|TMUS188.02+0.72 (+0.38%) ▲|TSLA376.37+19.36 (+5.42%) ▲|TXN253.83-0.97 (-0.38%) ▼|UBER75.96-0.49 (-0.64%) ▼|UNH400.94+1.28 (+0.32%) ▲|UNP289.15-0.58 (-0.20%) ▼|UPS103.50+0.49 (+0.48%) ▲|USB63.53+0.76 (+1.21%) ▲|V378.75+0.35 (+0.09%) ▲|VZ50.59+0.37 (+0.74%) ▲|WFC89.19-0.08 (-0.09%) ▼|WMT108.42+2.33 (+2.20%) ▲|XOM162.21-1.94 (-1.18%) ▼|AAPL328.21+3.25 (+1.00%) ▲|ABBV260.21-1.51 (-0.58%) ▼|ABT108.79-1.68 (-1.52%) ▼|ACN193.12+5.44 (+2.90%) ▲|ADBE285.75+5.96 (+2.13%) ▲|AMAT435.91-2.55 (-0.58%) ▼|AMD456.16-0.90 (-0.20%) ▼|AMGN444.12+1.28 (+0.29%) ▲|AMT177.75+4.83 (+2.79%) ▲|AMZN258.90+3.92 (+1.54%) ▲|AVGO357.16-10.08 (-2.74%) ▼|AXP329.82-0.16 (-0.05%) ▼|BA210.51+1.64 (+0.79%) ▲|BAC63.04+0.44 (+0.70%) ▲|BKNG195.13-4.47 (-2.24%) ▼|BLK1,126.15+19.07 (+1.72%) ▲|BMY68.09+0.43 (+0.64%) ▲|BNY164.33+2.29 (+1.41%) ▲|BRK-B508.13+2.89 (+0.57%) ▲|C138.14+3.80 (+2.83%) ▲|CAT800.14+7.86 (+0.99%) ▲|CL90.09-0.01 (-0.01%) ▼|CMCSA26.65-0.16 (-0.60%) ▼|COF220.50+3.90 (+1.80%) ▲|COP135.72-1.48 (-1.08%) ▼|COST925.41-3.07 (-0.33%) ▼|CRM264.43+7.50 (+2.92%) ▲|CSCO108.61-0.85 (-0.77%) ▼|CVS97.20-0.03 (-0.03%) ▼|CVX211.32-0.46 (-0.22%) ▼|DE694.41-3.96 (-0.57%) ▼|DHR211.03+1.12 (+0.53%) ▲|DIS107.16-0.82 (-0.76%) ▼|DUK121.40+0.84 (+0.70%) ▲|EMR150.21+1.23 (+0.83%) ▲|FDX324.31+7.77 (+2.45%) ▲|GD365.87+1.80 (+0.49%) ▲|GE333.48+3.98 (+1.21%) ▲|GEV941.84+19.90 (+2.16%) ▲|GILD151.22+1.61 (+1.08%) ▲|GM87.22+2.35 (+2.77%) ▲|GOOG339.08+5.30 (+1.59%) ▲|GOOGL342.48+5.36 (+1.59%) ▲|GS1,037.93+33.51 (+3.34%) ▲|HD318.07+1.89 (+0.60%) ▲|HON207.63+1.56 (+0.76%) ▲|IBM234.71+3.01 (+1.30%) ▲|INTC91.67+1.62 (+1.80%) ▲|INTU344.30+1.36 (+0.40%) ▲|ISRG369.83-2.05 (-0.55%) ▼|JNJ278.43+3.22 (+1.17%) ▲|JPM362.06+5.84 (+1.64%) ▲|KO88.81+0.57 (+0.65%) ▲|LIN482.19-3.66 (-0.75%) ▼|LLY1,159.60-0.48 (-0.04%) ▼|LMT532.95+1.40 (+0.26%) ▲|LOW201.90+2.06 (+1.03%) ▲|LRCX292.66+4.34 (+1.51%) ▲|MA585.71-2.43 (-0.41%) ▼|MCD259.63-1.32 (-0.51%) ▼|MDLZ61.45-1.00 (-1.60%) ▼|MDT93.10+0.92 (+1.00%) ▲|META610.68+17.83 (+3.01%) ▲|MMM168.31-0.44 (-0.26%) ▼|MO69.49-0.07 (-0.10%) ▼|MRK152.34+0.70 (+0.46%) ▲|MS217.15+5.33 (+2.52%) ▲|MSFT510.12+13.30 (+2.68%) ▲|MU958.16+2.08 (+0.22%) ▲|NEE84.06+0.96 (+1.16%) ▲|NFLX82.67-0.06 (-0.07%) ▼|NKE38.77+0.53 (+1.39%) ▲|NOW145.59+8.87 (+6.49%) ▲|NVDA228.45+4.04 (+1.80%) ▲|ORCL154.04+8.29 (+5.69%) ▲|PEP140.02-0.50 (-0.36%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG146.92-0.72 (-0.49%) ▼|PLTR182.53+13.07 (+7.71%) ▲|PM186.17-1.77 (-0.94%) ▼|QCOM168.57-0.47 (-0.28%) ▼|RTX202.13+1.35 (+0.67%) ▲|SBUX105.82-0.90 (-0.84%) ▼|SCHW110.38+2.14 (+1.98%) ▲|SO88.77+0.46 (+0.52%) ▲|SPG211.52+1.32 (+0.63%) ▲|T26.19+0.24 (+0.92%) ▲|TMO618.43+9.89 (+1.63%) ▲|TMUS188.02+0.72 (+0.38%) ▲|TSLA376.37+19.36 (+5.42%) ▲|TXN253.83-0.97 (-0.38%) ▼|UBER75.96-0.49 (-0.64%) ▼|UNH400.94+1.28 (+0.32%) ▲|UNP289.15-0.58 (-0.20%) ▼|UPS103.50+0.49 (+0.48%) ▲|USB63.53+0.76 (+1.21%) ▲|V378.75+0.35 (+0.09%) ▲|VZ50.59+0.37 (+0.74%) ▲|WFC89.19-0.08 (-0.09%) ▼|WMT108.42+2.33 (+2.20%) ▲|XOM162.21-1.94 (-1.18%) ▼|
23.7 C
New York
Friday, September 4, 2026

Tag: novel

newssourceFORcompanyinformationcontent1releasesmarket

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Global Times hosts China-Russia Literature Salon in Beijing

BEIJING, June 19, 2025 /PRNewswire/ -- To thoroughly study, promote, and implement Xi Jinping Thought on Culture and to advance mutual learning between Chinese and...

AI Prophet Zacharias Midjourney Launches Satirical Literary Cult Simulator Exploring AI Religion, Digital Ritual, and Blockchain Sacrament

New experience blends AI authorship, absurdist spirituality, performance theology, and interactive fiction via retro terminal and NFT-driven ritual 
New experience blends AI authorship, absurdist spirituality, performance theology, and interactive fiction via retro terminal and NFT-driven ritual

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2025.

HER2-low Cancers Market Set to Register Immense Growth at a CAGR of 9.4% During the Study Period (2020-2034) | DelveInsight

The future of the HER2-low cancer treatment market is poised for significant transformation, driven by the approval of ENHERTU and the advancement of other...

Delta-like Ligand 3 Targeted Therapies Market is Predicted to Heat Up During the Forecast Period (2025-2034) Across 7MM Owing to a Robust Pipeline |...

The delta-like ligand 3 targeted therapies market is witnessing significant growth, driven by the rising incidence of small cell lung cancer (SCLC) and neuroendocrine...

New Study Data on Chemo-Immunotherapy Approach Using the ELIAS Cancer Immunotherapy (ECI®) to Treat Bone Cancer in Dogs Demonstrates Improved Outcomes

LENEXA, Kan., June 19, 2025 /PRNewswire/ -- ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced interim results from an ongoing clinical...

CD5 Targeted Therapies CD5 Targeting CAR T Cell Therapy Clinical Trials Market Insight 2025

First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research 
First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research

RWJBarnabas Health, Rutgers Cancer Institute, Tufts Medical Center, and The University of Manchester Develop First Risk Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma

Research Published in NEJM Evidence and presented at the International Conference on Malignant Lymphoma NEW BRUNSWICK, N.J. and BOSTON, June 19, 2025 /PRNewswire/ -- Researchers from...

Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells

If approved, Zemcelpro® is expected to:increase access to donor-derived stem cell transplantation, which offers a potentially curative option for haematologic malignancies, including leukemias and myelodysplastic syndromesbe...

RyboDyn Selected to Join Lilly Gateway Labs to Advance Next-Gen Immunotherapies Targeting the Dark Proteome

Lilly Collaboration Accelerates RyboDyn's Dark Proteome Targets Toward First-in-Class Therapies SAN DIEGO, June 19, 2025 /PRNewswire/ -- RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies...

Memo Therapeutics AG to Present Interim Phase II Results of Potravitug for the Treatment of BKV Infection in Kidney Transplant Recipients in a Late...

PRESS RELEASE

Symbiotic.blue Launches to Combine Oxford and Cambridge Scientific Brain Power with Bioentrepreneurial Leadership to Reinvent AI Drug Discovery

LONDON, June 19, 2025 (GLOBE NEWSWIRE) -- Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven drug discovery (AIDD) platform by combining the power of generative AI with brain-inspired methodologies. Symbiotic.blue aims to create smarter, multi-targeted therapeutics to tackle complex diseases.

European Patent Office (EPO): Neeka and Leila Mashouf win the Nature Guardians prize at the Young Inventors Prize 2025 for turning CO₂ into essential...

28-year-old American scientists recognised for converting industrial CO₂ emissions into biodegradable celluloseTheir innovation offers a scalable, low-carbon alternative to textile productionThe European Patent Office...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNovel

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers